UBS raised the firm’s price target on HCA Healthcare (HCA) to $635 from $598 and keeps a Buy rating on the shares. HCA Healthcare could see its long-standing valuation range expand if AI-driven efficiency gains catalyze a re-rating, supported by its industry-leading margins, strong cash flow, and significant share repurchases, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $535 from $420 at JPMorgan
- MSFT Stock in the Spotlight as Microsoft Builds Its Own AI Model and Targets Healthcare
- HCA Healthcare Faces Rising Hurricane Risk Despite Insurance, Threatening Operations and Earnings
- HCA Healthcare price target raised to $541 from $503 at Bernstein
- HCA Healthcare price target raised to $540 from $520 at Mizuho